Bluejay Diagnostics Executes Reverse Stock Split Amid Clinical Trial Progress

Bluejay Diagnostics US0956331039

Bluejay Diagnostics has completed its previously announced reverse stock split, consolidating its share structure on a 1-for-4 basis. This corporate action, which became effective in late January, significantly reduces the number of shares outstanding and refocuses investor attention on the company's operational milestones, particularly its pivotal sepsis diagnostic trial and regulatory pathway.

The primary effect of the 1-for-4 reverse stock split was a reduction in the number of outstanding shares from approximately 2.83 million to about 708,533. Such consolidations are commonly utilized by publicly traded companies to adjust share price levels and meet certain listing requirements. With this technical adjustment now complete, the market's focus shifts to Bluejay's core business developments.

Central to the company's strategy is the ongoing SYMON-II clinical study. This trial is designed to validate the performance of Bluejay's Symphony IL-6 test in predicting 28-day mortality risk for sepsis patients. As of November 2025, patient recruitment for this critical study was reported to be 50% complete. Management anticipates finalizing the trial by the end of 2026, a key step before seeking regulatory approval.

Manufacturing Advancements and Strategic Partnerships

Beyond the clinical work, Bluejay has reported significant progress in its manufacturing capabilities. In December, the company successfully completed the commercial-scale production of antibodies essential for detecting the protein Interleukin-6 (IL-6). This biomarker is a crucial indicator of inflammatory processes in critical care settings.

The company has also fortified its supply chain through extended collaborations with key partners. An agreement with Toray Industries for the production of test cassettes has been extended through October 2026. Furthermore, a manufacturing partnership with SanyoSeiko for the Symphony analyzer devices remains firmly in place, ensuring production readiness.

Funding and Forward-Looking Regulatory Goals

The company's near-term objectives are explicitly tied to its financial runway. In October 2025, Bluejay bolstered its balance sheet through a private placement that raised $4.5 million. However, the stated goal of submitting for U.S. Food and Drug Administration (FDA) clearance in 2027 is contingent upon securing additional follow-on financing.

For the remainder of the year, investor attention is likely to remain fixed on the pace of enrollment in the SYMON-II study. The company's ability to advance this trial, supported by its strengthened manufacturing partnerships and recent capital infusion, will be critical as it works toward its 2027 regulatory submission target.